Decitabine: a historical review of the development of an epigenetic drug

The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vos, Dick, van Overveld, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2005
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103145/
https://www.ncbi.nlm.nih.gov/pubmed/16220311
http://dx.doi.org/10.1007/s00277-005-0008-x
Descripción
Sumario:The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.

Ejemplares similares